Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Purpose There is concern that regenerative cell-based therapies at the site of malignant primary bone tumours could result in increased risk of local tumour recurrence. We therefore investigated the long-term risks for site-specific recurrences in patients who had received an autologous bone marrow derived mesenchymal stem cell suspension to improve healing at the host-to-allograft bone junction of the reconstruction after bone tumour resection. Methods A total of 92 patients were treated from 1993 to 2003 with bone marrow-derived mesenchymal stem cells after bone tumour resection. Patients were monitored for cancer incidence from the date of first operation (1993) until death, or until 31 December 2013. The mean follow-up time was 15.4 years (range ten to 20 years). The average number of MSCs returned to the patient was 234,000 MSCs ± 215,000. The primary outcome was to evaluate the risk of tumorigenesis recurrence at the cell therapy treatment sites with radiographs and/or MRIs. The relative risk of cancer recurrence was expressed as the ratio of observed and expected number of cases according to three different control populations. Results Thirteen recurrences were found at the treatment sites among the 92 patients. The expected number of recurrences based on incidence in the three cohort populations was between 15 and 20 for the same cancer, age and sex distribution. The standardized incidence ratio (equal to observed cancers divided by expected cancers) for the entire fo…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is preliminary clinical evidence for mesenchymal stromal cell in promoting bone regeneration within large bone defects after surgical excision.”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
In the citing paper
“They found no increase in the risk of local recurrence for all cancer types [100].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
In the citing paper
“Using three control groups, they concluded that the use of MSCs is probably safe, demonstrating no increase in the risk of local recurrence for all cancer types [100].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [100]
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J., & Canadian Critical Care Trials Group (2012) · PLoS ONE · doi:10.1371/journal.pone.0047559 · Cited by 1,146 · cited 1×
“Many experimental studies [7, 12, 27, 31, 33, 35, 52] in vitro and in animals have been performed to identify the MSC mediators acting on bone tumours cells.”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 1×
“Controversial results have been reported when MSCs have been injected into mice with induced tumour, resulting either in promotion or inhibition of tumour growth depending on the studies [40, 42].”
BackgroundStudeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh299 · Cited by 842
Review: Mesenchymal Stem Cells: Cell–Based Reconstructive Therapy in Orthopedics
Caplan, A. I. (2005) · Tissue Engineering · doi:10.1089/ten.2005.11.1198 · Cited by 822
Hernigou, P. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02215 · Cited by 787 · cited 2×
“The bone marrow aspirate was transferred immediately [22] to the processing laboratory, where the nucleated cells (including progenitor cells) were isolated by using a cell separator (Cobe 2991; Gambo BCT, Paris, France).”
BackgroundMethodSelf-citationFat Grafting to the Breast Revisited: Safety and Efficacy
Coleman, S. R., & Saboeiro, A. P. (2007) · Plastic and Reconstructive Surgery · doi:10.1097/01.prs.0000252001.59162.c9 · Cited by 724
Robison, L. L., Armstrong, G. T., Boice, J. D., Chow, E. J., Davies, S. M., Donaldson, S. S., Green, D. M., Hammond, S., Meadows, A. T., Mertens, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3339 · Cited by 669
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Tolar, J., Nauta, A. J., Osborn, M. J., Panoskaltsis Mortari, A., McElmurry, R. T., Bell, S., Xia, L., Zhou, N., Riddle, M., Schroeder, T. M., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2005-0620 · Cited by 639 · cited 2×
“During this period there was no discussion as there is today about relationship between bone tumours and MSCs [16, 47] and particularly that MSCs might be the progenitors of Ewing sarcoma [1].”
BackgroundResultAntitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597 · cited 1×
“Controversial results have been reported when MSCs have been injected into mice with induced tumour, resulting either in promotion or inhibition of tumour growth depending on the studies [40, 42].”
BackgroundStem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis
Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., Ghivizzani, S. C., Ignatova, T. N., & Steindler, D. A. (2005) · Neoplasia · doi:10.1593/neo.05394 · Cited by 492 · cited 2×
“A major concern today in the application of regenerative therapies after cancer, especially cell-based therapies, is whether these new treatments will increase the risk of local tumour recurrence, particularly at the site of a tumour resection [16].”
BackgroundBacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4016 · Cited by 438
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype
Naumov, G. N., Bender, E., Zurakowski, D., Kang, S.-Y., Sampson, D., Flynn, E., Watnick, R. S., Straume, O., Akslen, L. A., Folkman, J., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj068 · Cited by 423 · cited 2×
“The notion of cancer dormancy [13, 43, 49] is Fig.”
BackgroundPercutaneous Autologous Bone-Marrow Grafting for Nonunions: Surgical Technique
Hernigou, P., Mathieu, G., Poignard, A., Manicom, O., Beaujean, F., & Rouard, H. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.f.00203 · Cited by 382
Self-citationConcise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Lazennec, G., & Jorgensen, C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1006 · Cited by 255
J. Centeno, C., R. Schultz, J., Cheever, M., Freeman, M., Faulkner, S., Robinson, B., & Hanson, R. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811797904371 · Cited by 234
Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells
Hernigou, P., Homma, Y., Flouzat Lachaniette, C. H., Poignard, A., Allain, J., Chevallier, N., & Rouard, H. (2013) · International Orthopaedics · doi:10.1007/s00264-013-2017-z · Cited by 226 · cited 1×
“The dilution of nucleated cells coming from the bone marrow by cells in the peripheral blood was calculated as previously described [24].”
MethodSelf-citationXu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206 · cited 1×
“Many experimental studies [7, 12, 27, 31, 33, 35, 52] in vitro and in animals have been performed to identify the MSC mediators acting on bone tumours cells.”
BackgroundTumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures
Demicheli, R., Retsky, M. W., Hrushesky, W. J., & Baum, M. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0999 · Cited by 205 · cited 1×
“The notion of cancer dormancy [13, 43, 49] is Fig.”
BackgroundMorishita, T., Honoki, K., Ohgushi, H., Kotobuki, N., Matsushima, A., & Takakura, Y. (2006) · Artificial Organs · doi:10.1111/j.1525-1594.2006.00190.x · Cited by 178 · cited 1×
“Although controversial, MSCs expanded in vitro and seeded on hydroxyapatite scaffolds have been used to heal defects derived from curettage of a bone tumour as an alternative to autologous bone grafting [41].”
BackgroundSurvival Data for 648 Patients with Osteosarcoma Treated at One Institution
Mankin, H. J., Hornicek, F. J., Rosenberg, A. E., Harmon, D. C., & Gebhardt, M. C. (2004) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000145991.65770.e6 · Cited by 173 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells
Djouad, F., Bony, C., Apparailly, F., Louis-Plence, P., Jorgensen, C., & Noël, D. (2006) · Transplantation · doi:10.1097/01.tp.0000236098.13804.0b · Cited by 134 · cited 2×
“Previous studies [12, 47] suggesting that MSC would be the most plausible cell of origin of Ewing sarcomas have stressed the need for deeper studies of BM-MSC derived from Ewing sarcomas patients.”
BackgroundResultSafety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120 · cited 1×
“[45], whereby a patient in complete remission of an humerus telangiectasic osteosarcoma for ten years consulted for a cosmetic correction by lipofilling.”
BackgroundLong-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy
Kinsella, T. J., Miser, J. S., Waller, B., Venzon, D. J., GLATSTEIN, E. J., Weaver‐McClure, L., & Horowitz, M. E. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90047-8 · Cited by 113 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Hernigou, P., Homma, Y., Flouzat–Lachaniette, C.-H., Poignard, A., Chevallier, N., & Rouard, H. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.m.00261 · Cited by 101 · cited 1×
“[23] reported that 1,873 healthy (non-sarcoma affected) patients, treated for various orthopaedic conditions by implanting autologous concentrated bone marrow MSCs, did not experience more evident neoplasic complication than the general population, while some patients reached 20 years of follow-up.”
BackgroundSelf-citationLéotot, J., Coquelin, L., Bodivit, G., Bierling, P., Hernigou, P., Rouard, H., & Chevallier, N. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.02.003 · Cited by 87 · cited 1×
“Furthermore, MSCs when expanded in short-term culture [9, 36] are able to survive several weeks.”
BackgroundSelf-citationLate Recurrence in Pediatric Cancer: A Report From the Childhood Cancer Survivor Study
Wasilewski-Masker, K., Liu, Q., Yasui, Y., Leisenring, W., Meacham, L. R., Hammond, S., Meadows, A. T., Robison, L. L., & Mertens, A. C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp417 · Cited by 78 · cited 3×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
BackgroundResultImpact of close surgical margin on local recurrence and survival in osteosarcoma
Li, X., Moretti, V. M., Ashana, A. O., & Lackman, R. D. (2011) · International Orthopaedics · doi:10.1007/s00264-011-1230-x · Cited by 76 · cited 1×
“Regarding the bone margin [37], the issue is how close we can approach the tumour to save a nearby joint or the host bone stock to improve longevity of implants.”
BackgroundMassive allografts sterilised by irradiation. Clinical results
Hernigou, P., Delépine, G., GOUTALLIER, D., & Julieron, A. (1993) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.75b6.8245080 · Cited by 66
Self-citationLate relapse of osteosarcoma: Implications for follow‐up and screening
Strauss, S. J., McTiernan, A., & Whelan, J. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20154 · Cited by 59 · cited 1×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
ResultHernigou, P., Pariat, J., Queinnec, S., Homma, Y., Flouzat–Lachaniette, C.-H., Chevallier, N., & Rouard, H. (2014) · International Orthopaedics · doi:10.1007/s00264-014-2285-2 · Cited by 55 · cited 1×
“The addition of MSCs to whole bone allografts in patients without sarcoma was proposed to support the formation of a new vasculature and promote better graft incorporation [25, 26].”
BackgroundSelf-citationAmaral, A. T., Manara, M. C., Berghuis, D., Ordóñez, J. L., Biscuola, M., López‐García, M. Á., Osuna, D., Lucarelli, E., Alviano, F., Lankester, A. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085814 · Cited by 53
Kubista, B., Klinglmueller, F., Bilban, M., Pfeiffer, M., Lass, R., Giurea, A., Funovics, P. T., Toma, C. D., Dominkus, M., Kotz, R. I., et al. (2010) · International Orthopaedics · doi:10.1007/s00264-010-0996-6 · Cited by 42 · cited 1×
“Regardless of the mechanism by which subclinical tumour persists, it is useful to hypothesize that dormancy is an intrinsic characteristic [30] of the resting tumour cell.”
BackgroundNilbert, M. C., Sæter, G., Elomaa, I., Monge, O. R., Wiebe, T., & Alvegård, T. A. (1998) · Acta Oncologica · doi:10.1080/028418698430601 · Cited by 41
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Cesari, M., Longhi, A., & Bacci, G. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000212944.82361.1d · Cited by 40 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Lee, O. K., Coathup, M. J., Goodship, A. E., & Blunn, G. W. (2005) · Tissue Engineering · doi:10.1089/ten.2005.11.1727 · Cited by 38 · cited 1×
“Many experimental studies [7, 12, 27, 31, 33, 35, 52] in vitro and in animals have been performed to identify the MSC mediators acting on bone tumours cells.”
BackgroundLong‐term outcome of patients with monostotic Ewing's sarcoma treated with combined modality
Gasparini, M., Lombardi, F., Ballerini, E., Gandola, L., Gianni, M. C., Massimino, M., Rottoli, L., & Fossati‐Bellani, F. (1994) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950230504 · Cited by 34 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Coquelin, L., Fialaire, A., Roux, S., Poignard, A., Bierling, P., Hernigou, P., Chevallier, N., & Rouard, H. (2012) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0645 · Cited by 33 · cited 1×
“Furthermore, MSCs when expanded in short-term culture [9, 36] are able to survive several weeks.”
BackgroundSelf-citationHernigou, P., Gras, G. S., Marinello, G., & Dormont, D. (2000) · Cell and Tissue Banking · doi:10.1023/a:1010177406541 · Cited by 32 · cited 1×
“All bone graft was obtained from the National Blood and Tissue Services and had undergone the irradiation using 25 KGy [18] to prevent infection transmission [20, 21].”
MethodSelf-citationLong‐term survival in patients with Ewing's sarcoma relapsing after completing therapy
Hayes, F. A., Thompson, E. I., Kumar, M., & Hustu, H. O. (1987) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950150506 · Cited by 27 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Supercharging allografts with mesenchymal stem cells in the operating room during hip revision
Homma, Y., Kaneko, K., & Hernigou, P. (2013) · International Orthopaedics · doi:10.1007/s00264-013-2221-x · Cited by 27 · cited 1×
“The addition of MSCs to whole bone allografts in patients without sarcoma was proposed to support the formation of a new vasculature and promote better graft incorporation [25, 26].”
BackgroundSelf-citationHernigou, P., Gras, G. S., Marinello, G., & Dormont, D. (2000) · Acta Orthopaedica Scandinavica · doi:10.1080/000164700317381225 · Cited by 27
Self-citationThariat, J., Italiano, A., Peyrade, F., Birtwisle‐Peyrottes, I., Gastaud, L., Dassonville, O., & Thyss, A. (2008) · Sarcoma · doi:10.1155/2008/854141 · Cited by 20 · cited 1×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
ResultA model of tumor cell dormancy: Effects of anesthesia and surgery
Varani, J., Lovett, E. J., & Lundy, J. (1981) · Journal of Surgical Oncology · doi:10.1002/jso.2930170103 · Cited by 19 · cited 1×
“The notion of cancer dormancy [13, 43, 49] is Fig.”
BackgroundLocal Recurrence of Parosteal Osteosarcoma Adjacent to a Prosthesis after 20 Years: A Case Report
Lau, T., Wong, J., Yip, D., Chien, E., Shek, T., & Wong, L. (2004) · Journal of orthopaedic surgery · doi:10.1177/230949900401200225 · Cited by 16 · cited 1×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
ResultLucarelli, E., Bellotti, C., Mantelli, M., Avanzini, M. A., Maccario, R., Novara, F., Arrigo, G., Zuffardi, O., Zuntini, M., Pandolfi, M., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-95 · Cited by 15 · cited 1×
“[38] evaluated the in vitro biosafety profiles of BM-derived MSCs from osteosarcoma and Ewing sarcomas patients as compared to those of BM-MSCs from control healthy donors after expansion under the same culture conditions.”
ResultGamma probe radioguided parathyroid forearm surgery in recurrent hyperparathyroidism
Cutress, R., Manwaring-White, C., Dixon, K., Dhir, A., & Skene, A. (2009) · Annals of The Royal College of Surgeons of England · doi:10.1308/147870809x401047 · Cited by 12
Local recurrence of osteosarcoma after 17 years
Welck, M., Gikas, P. D., Pearce, P., Bhumbra, R. S., Briggs, T. W. R., & Cannon, S. R. (2009) · Annals of The Royal College of Surgeons of England · doi:10.1308/147870809x400967 · Cited by 7 · cited 1×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
ResultLATE RECURRENCE IN PRIMARY REGION OF PAROSTEAL OSTEOSARCOMA: A CASE REPORT
Köksal, Y., Akyüz, C., Varan, A., Atılla, B., Gedikog̈lu, G., & Büyükpamukçu, M. (2008) · Pediatric Hematology and Oncology · doi:10.1080/08880010701621010 · Cited by 4 · cited 1×
“6 % that appears to conform to the other series in the literature [2, 3, 14, 15, 17, 28, 29, 39] for the main tumours (osteosarcoma, chondrosarcoma, and Ewing sarcoma).”
Late recurrence of osteosarcoma
Le, B. H. C., Buchanan, M., Steer, C., & Boer, R. D. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01346.x · Cited by 4 · cited 1×
“If five-year disease-free survival is often interpreted to mean “cure” this study as other studies [34, 44, 46, 48, 50, 51] demonstrates that most diseasefree survivors will be “cured” five years from diagnosis, but there remain survivors among all diagnoses at risk for late local recurrence [32].”
ResultBone Union in Allografts: Chemotherapy Considerations
Delépine, N., Delépine, G., Hernigou, P., & GOUTALLIER, D. (1991) · Springer eBooks · doi:10.1007/978-3-642-75879-9_15 · Cited by 2
Self-citation
Research works printed but not linked: 2
- Delepine G, Delepine N, Hernigou P (1991) Allograft with patellar tendon in reconstructive procedures after upper tibial resection. Limb Salvage Ed., Springer, pp 436–437
- Hernigou P, Beaujean F (1997) Autologous bone marrow to stimulate bone healing. J Cell Eng 2(3):113–116
Cited by
Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress
Hernigou, P., Trousselier, M., Roubineau, F., Bouthors, C., Chevallier, N., Rouard, H., & Flouzat–Lachaniette, C.-H. (2016) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2016.8.1.1 · Cited by 147
Self-citationPerforming a Better Bone Marrow Aspiration
Friedlis, M. F., & Centeno, C. J. (2016) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2016.06.009 · Cited by 42
Avril, P., Le Nail, L.-R., Brennan, M. Á., Rosset, P., De Pinieux, G., Layrolle, P., Heymann, D., Perrot, P., & Trichet, V. (2016) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.11.002 · Cited by 38
“reported that the autologous concentrated bone marrow cell adjuvant therapy in 92 patients treated after bone tumor resection did not increase the risk of local tumor recurrence compared to control populations [63].”
BackgroundNew Advances in Stem Cell Therapy for Osteonecrosis of the Femoral Head
Zhou, W. J., Ming, Q., Lv, Y., & Zhu, J. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x13666181025120252 · Cited by 38
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
Metadata
- Authors
- Hernigou, P., Flouzat Lachaniette, C. H., Delambre, J., Chevallier, N., & Rouard, H.
- Affiliations
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Corresponding author
- Hernigou, Philippe
- Venue
- International Orthopaedics
- Published
- 2014-06-07
- Volume
- 38
- Issue
- 9
- Pages
- 1825-1835
- ISSN
- 0341-2695 (ISSN-L)
- 1432-5195
- OpenAlex
- W1965962463
- Cited by
- 22
- References
- 52
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 1
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Orthopaedics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- mesenchymal stem cells, bone tumor resection, local recurrence, carcinogenesis, autologous cell therapy, bone marrow-derived stem cells, bone reconstruction, cancer risk, long-term follow-up, standardized incidence ratio
- MeSH terms
- Adolescent, Adult, Bone Neoplasms, Bone Regeneration, Child, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, Time Factors, Incidence, Bone Transplantation, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.